Wall Street Zen Downgrades Kiniksa Pharmaceuticals International (NASDAQ:KNSA) to Buy

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) was downgraded by equities researchers at Wall Street Zen from a “strong-buy” rating to a “buy” rating in a research note issued on Sunday.

Other analysts have also recently issued research reports about the stock. Wells Fargo & Company raised their price objective on shares of Kiniksa Pharmaceuticals International from $42.00 to $45.00 and gave the company an “overweight” rating in a research note on Thursday, September 25th. Weiss Ratings reiterated a “hold (c)” rating on shares of Kiniksa Pharmaceuticals International in a research note on Wednesday, October 8th. Citigroup raised their price objective on shares of Kiniksa Pharmaceuticals International from $45.00 to $50.00 and gave the company a “buy” rating in a research note on Friday, October 17th. Wedbush restated an “outperform” rating and set a $48.00 target price (up previously from $44.00) on shares of Kiniksa Pharmaceuticals International in a research report on Tuesday, October 28th. Finally, The Goldman Sachs Group lifted their target price on shares of Kiniksa Pharmaceuticals International from $45.00 to $55.00 and gave the stock a “buy” rating in a research report on Wednesday. Seven analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $50.29.

Kiniksa Pharmaceuticals International Stock Performance

Shares of Kiniksa Pharmaceuticals International stock opened at $37.01 on Friday. Kiniksa Pharmaceuticals International has a 1 year low of $17.82 and a 1 year high of $42.05. The company has a market capitalization of $2.74 billion, a P/E ratio of 82.25 and a beta of 0.16. The company’s fifty day moving average is $36.91 and its two-hundred day moving average is $31.13.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last issued its quarterly earnings data on Tuesday, November 4th. The company reported $0.23 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.31 by ($0.08). Kiniksa Pharmaceuticals International had a return on equity of 7.46% and a net margin of 6.01%.The business had revenue of $180.85 million for the quarter, compared to analysts’ expectations of $166.64 million. During the same period in the previous year, the business posted ($0.18) earnings per share. The company’s revenue for the quarter was up 61.2% on a year-over-year basis. As a group, equities analysts expect that Kiniksa Pharmaceuticals International will post -0.55 earnings per share for the current year.

Insider Buying and Selling at Kiniksa Pharmaceuticals International

In other news, COO Eben Tessari sold 12,368 shares of the stock in a transaction on Tuesday, October 14th. The shares were sold at an average price of $37.67, for a total value of $465,902.56. Following the completion of the sale, the chief operating officer owned 28,684 shares of the company’s stock, valued at $1,080,526.28. This represents a 30.13% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Sanj K. Patel sold 97,390 shares of the firm’s stock in a transaction on Wednesday, October 22nd. The shares were sold at an average price of $38.83, for a total transaction of $3,781,653.70. Following the sale, the chief executive officer directly owned 111,794 shares of the company’s stock, valued at approximately $4,340,961.02. The trade was a 46.56% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 905,398 shares of company stock worth $32,347,674 over the last three months. 53.48% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Kiniksa Pharmaceuticals International

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Rubric Capital Management LP grew its holdings in Kiniksa Pharmaceuticals International by 15.6% during the 2nd quarter. Rubric Capital Management LP now owns 3,909,806 shares of the company’s stock worth $108,184,000 after acquiring an additional 526,567 shares in the last quarter. Vanguard Group Inc. grew its holdings in Kiniksa Pharmaceuticals International by 4.7% during the 1st quarter. Vanguard Group Inc. now owns 3,359,101 shares of the company’s stock worth $74,606,000 after acquiring an additional 151,604 shares in the last quarter. Acadian Asset Management LLC grew its holdings in Kiniksa Pharmaceuticals International by 22.6% during the 2nd quarter. Acadian Asset Management LLC now owns 1,267,989 shares of the company’s stock worth $35,067,000 after acquiring an additional 233,668 shares in the last quarter. Qube Research & Technologies Ltd boosted its holdings in shares of Kiniksa Pharmaceuticals International by 277.8% in the 2nd quarter. Qube Research & Technologies Ltd now owns 888,364 shares of the company’s stock valued at $24,581,000 after buying an additional 653,236 shares during the period. Finally, Millennium Management LLC boosted its holdings in shares of Kiniksa Pharmaceuticals International by 8.7% in the 1st quarter. Millennium Management LLC now owns 847,124 shares of the company’s stock valued at $18,815,000 after buying an additional 67,452 shares during the period. Hedge funds and other institutional investors own 53.95% of the company’s stock.

About Kiniksa Pharmaceuticals International

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.